16.1 million American adults, or about 6.7% of the adult U.S. population, are affected by major depressive disorder.

Worldwide, over 300 million individuals suffer from depression. Despite the availability of over 25 FDA approved drugs for depression, a significant portion of patients experience poor outcomes.

Only 35% of patients on SSRIs experience full remission of symptoms. The rest experience temporary and/or partial relief. More so, about 30% of all patients with depression don’t respond adequately to the available treatments. As many as 5 million people in the U.S. have treatment-resistant depression.

Selecting an effective medication is a taxing trial-and-error process. Impact of a medication can take weeks to appear. Patients with postpartum depressive disorder have no effective solutions, as most don’t want to take currently available drugs.

Scientists are gaining a more nuanced picture of depression. It is not a monolithic disease, but rather, dozens of distinct maladies each with multiple contributors.

uMETHOD is currently developing a combination therapy approach to advance the care of patients with major depressive disorder. We intend to provide hope to the 65% of patients not adequately served by the standard-of-care.

Patients and physicians can sign up below to receive updates on our progress.